NEO
NeoGenomicsBNasdaq / Health Care Equipment & Services
Last Price
At close
2026-07-23
Current thesis
Rising test volumes, stable reimbursement, and successful roll-out of higher‑margin panels drive above‑consensus revenue growth and multiple expansion, supporting upside toward the bull target within 12 months.
Posture
Constructive
Lead driver
Momentum
What changed
Next scheduled catalyst: earnings 2026-07-28 · AMC.
What can break
Competition from liquid-biopsy and centralized labs
Momentum
99
Value
42
Sentiment
49
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $13.50 · Bull $16.50 · Bear $9.00
Earnings
2026-07-28 · AMC
Data freshness
Prices
As of 2026-07-23
Fundamentals
As of 2026-07-22 • Vendor: Data Vendor v1
Scores
As of 2026-07-23 • Model: HYBRID_IC_RP
AI Memo
As of 2026-01-07 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-07-23
Investment thesis
As of 2026-07-23
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $16.22
Why
Momentum99 · Δ7d -0.5
Value42 · Δ7d -0.0
Sentiment49 · Δ7d +2.5
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
99
26% active weight
Current posture
7d trendFlat
Δ7d
-0.5
Δ21d
+0.7
Value
42
39% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+0.2
Sentiment
49
34% active weight
Current posture
7d trendImproving
Δ7d
+2.5
Δ21d
+3.4
Why this grade
Composite grade B. Momentum 98.6 / Value 41.6 / Sentiment 49.0
Fundamentals (TTM)As of 2026-07-22
Fundamentals (TTM)
As of 2026-07-22
Market Cap
$1.82B
Beta
1.57
Shares Out
130.21M
P/E (TTM) · Derived
-16.6
P/S (TTM)
2.20
P/FCF (TTM) · Derived
-363.90
Rev YoY
+11.1%
EPS YoY
-34.9%
Gross Margin
+40.9%
Op Margin
-17.0%
Net Debt
$249.84M
Current Ratio
4.42
As of 2026-07-23 • Updated nightlySource: Internal modelMethodology